Multivariate analysis of dosage of remimazolam for induction of general anaesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400085666

Enrollment

Unknown

Registered

2024-06-14

Start date

2024-06-20

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anaesthesia

Interventions

Small dose group:Ramazolam dose is gradually added

medium dose group:Ramazolam dose is gradually added

large dose group:Ramazolam dose is gradually added

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. To undergo general anesthesia; 2.ASA grade 1-2; 3 Age above 18 years old, below 80 years old; 4. The subjects give informed consent and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Combined with intellectual or conscious disorders; 2. Inability to understand anxiety rating scales; 2. Serious systemic disease, ASA grade 3-4; 3. Long-term oral sedation due to insomnia and other factors; 4. A history of drug use or opioid use.

Design outcomes

Secondary

Measure	Time frame
Body Mass Index;	—

Primary

Measure	Time frame
Remazolam dosage;Hemoglobin;blood pressure;heart rate;Self-Rating Anxiety Scale;	—

Countries

China

Contacts

Public ContactRen Zhanjie

Affiliated Hospital of Weifang Medical University

ren20041002@163.com+86 135 1638 5010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026